Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August9, 2017, Portola Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02 | Financial Statements and Exhibits |
(d) Exhibits
|
Number |
Description of Document |
| 99.1 | Press release entitled “Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update” dated August 9, 2017. |
PORTOLA PHARMACEUTICALS INC ExhibitEX-99.1 2 d398993dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO,…To view the full exhibit click here
About Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.